Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 56

1.

Effectiveness of the traditional Japanese Kampo medicine Yokukansan for chronic migraine: A case report.

Akiyama H, Hasegawa Y.

Medicine (Baltimore). 2019 Sep;98(36):e17000. doi: 10.1097/MD.0000000000017000.

2.

A case of severe pneumonitis with alveolar hemorrhage associated with herbal medicines.

Omori M, Saito Y, Miura Y, Tanaka T, Kashiwada T, Atsumi K, Hayashi H, Minegishi Y, Fujita K, Azuma A, Seike M, Gemma A.

J Nippon Med Sch. 2019 May 17. doi: 10.1272/jnms.JNMS.2019_86-504. [Epub ahead of print]

3.

Chotosan ameliorates cognitive impairment and hippocampus neuronal loss in experimental vascular dementia via activating the Nrf2-mediated antioxidant pathway.

Jiang P, Chen L, Sun J, Li J, Xu J, Liu W, Feng F, Qu W.

J Pharmacol Sci. 2019 Feb;139(2):105-111. doi: 10.1016/j.jphs.2018.12.003. Epub 2018 Dec 22.

4.

A review on chitosan centred scaffolds and their applications in tissue engineering.

Ahmed S, Annu, Ali A, Sheikh J.

Int J Biol Macromol. 2018 Sep;116:849-862. doi: 10.1016/j.ijbiomac.2018.04.176. Epub 2018 May 3. Review.

PMID:
29730001
5.

Nanostructured lipid carrier-based pH and temperature dual-responsive hydrogel composed of carboxymethyl chitosan and poloxamer for drug delivery.

Yu Y, Feng R, Yu S, Li J, Wang Y, Song Y, Yang X, Pan W, Li S.

Int J Biol Macromol. 2018 Jul 15;114:462-469. doi: 10.1016/j.ijbiomac.2018.03.117. Epub 2018 Mar 22.

PMID:
29578017
6.

Biologically anchored chitosan/gelatin-SrHAP scaffold fabricated on Titanium against chronic osteomyelitis infection.

David N, Nallaiyan R.

Int J Biol Macromol. 2018 Apr 15;110:206-214. doi: 10.1016/j.ijbiomac.2017.11.174. Epub 2017 Nov 29.

PMID:
29197567
7.

Cu(II)-carboxymethyl chitosan-silane schiff base complex grafted on nano silica: Structural evolution, antibacterial performance and dye degradation ability.

Naz A, Arun S, Narvi SS, Alam MS, Singh A, Bhartiya P, Dutta PK.

Int J Biol Macromol. 2018 Apr 15;110:215-226. doi: 10.1016/j.ijbiomac.2017.11.112. Epub 2017 Nov 21.

PMID:
29169947
8.

Neuroprotection by chotosan, a Kampo formula, against glutamate excitotoxicity involves the inhibition of GluN2B-, but not GluN2A-containing NMDA receptor-mediated responses in primary cultured cortical neurons.

Sasaki-Hamada S, Suzuki A, Sanai E, Matsumoto K, Oka JI.

J Pharmacol Sci. 2017 Nov;135(3):134-137. doi: 10.1016/j.jphs.2017.10.009. Epub 2017 Nov 1.

9.

Choto-san versus placebo for patients with dementia: systematic review and meta-analysis.

Imai H, Takeshima N, Oda H, Chen P, Sawada E, Furukawa TA.

Psychogeriatrics. 2017 Nov;17(6):466-478. doi: 10.1111/psyg.12275. Epub 2017 Jun 6. Review.

PMID:
28589702
10.

Doxorubicin Loaded Chitosan-W18 O49 Hybrid Nanoparticles for Combined Photothermal-Chemotherapy.

Yuan S, Hua J, Zhou Y, Ding Y, Hu Y.

Macromol Biosci. 2017 Aug;17(8). doi: 10.1002/mabi.201700033. Epub 2017 Apr 4.

PMID:
28374909
11.

Serotonergic and dopaminergic systems are implicated in antidepressant-like effects of chotosan, a Kampo formula, in mice.

Sasaki-Hamada S, Suzuki A, Ueda Y, Matsumoto K, Oka JI.

J Pharmacol Sci. 2017 Feb;133(2):110-113. doi: 10.1016/j.jphs.2017.01.002. Epub 2017 Jan 26.

12.

Statistical optimization of chitosan nanoparticles as protein vehicles, using response surface methodology.

Kiaie N, Aghdam RM, Tafti SH, Emami SH.

J Appl Biomater Funct Mater. 2016 Nov 2;14(4):e413-e422. doi: 10.5301/jabfm.5000278.

PMID:
27647390
13.

Chotosan improves Aβ1-42-induced cognitive impairment and neuroinflammatory and apoptotic responses through the inhibition of TLR-4/NF-κB signaling in mice.

Chen L, Hu L, Zhao J, Hong H, Feng F, Qu W, Liu W.

J Ethnopharmacol. 2016 Sep 15;191:398-407. doi: 10.1016/j.jep.2016.03.038. Epub 2016 Mar 16.

PMID:
26994819
14.

[]Improving effects of chotosan on the brain malfunction in rodent's disease models].

Oka J, Matsumoto K, Sasaki-Hamada S.

Nihon Yakurigaku Zasshi. 2016 Mar;147(3):157-60. doi: 10.1254/fpj.147.157. Japanese. No abstract available.

PMID:
26960776
15.

Protective effects of a Chotosan Fraction and its active components on β-amyloid-induced neurotoxicity.

Wei M, Chen L, Liu J, Zhao J, Liu W, Feng F.

Neurosci Lett. 2016 Mar 23;617:143-9. doi: 10.1016/j.neulet.2016.02.019. Epub 2016 Feb 12.

PMID:
26876445
16.

Chemical profiling with HPLC-FTMS of exogenous and endogenous chemicals susceptible to the administration of chotosan in an animal model of type 2 diabetes-induced dementia.

Niu Y, Li F, Inada C, Tanaka K, Watanabe S, Fujiwara H, Sasaki-Hamada S, Oka J, Matsumoto K.

J Pharm Biomed Anal. 2015 Feb;104:21-30. doi: 10.1016/j.jpba.2014.11.019. Epub 2014 Nov 18.

PMID:
25459756
17.

Inhibitory activities of selected Kampo formulations on human aldose reductase.

Onoda T, Ishikawa C, Fukazawa T, Li W, Obayashi M, Koike K.

BMC Complement Altern Med. 2014 Nov 6;14:435. doi: 10.1186/1472-6882-14-435.

18.

Chotosan, a Kampo formula, ameliorates hippocampal LTD and cognitive deficits in juvenile-onset diabetes rats.

Sasaki-Hamada S, Tamaki K, Otsuka H, Ueno T, Sacai H, Niu Y, Matsumoto K, Oka J.

J Pharmacol Sci. 2014;124(2):192-200. Epub 2014 Jan 29.

19.

Kampo formulations, chotosan, and yokukansan, for dementia therapy: existing clinical and preclinical evidence.

Matsumoto K, Zhao Q, Niu Y, Fujiwara H, Tanaka K, Sasaki-Hamada S, Oka J.

J Pharmacol Sci. 2013;122(4):257-69. Epub 2013 Jul 25. Review.

20.

Pharmacological characteristics of Kampo medicine as a mixture of constituents and ingredients.

Satoh H.

J Integr Med. 2013 Jan;11(1):11-6. doi: 10.3736/jintegrmed2013003. Review.

PMID:
23464641

Supplemental Content

Loading ...
Support Center